TY - JOUR T1 - Review: vaccines against human papillomavirus prevent cervical cancer precursors in young women for at least 3 years JF - Evidence Based Medicine JO - Evid Based Med SP - 168 LP - 168 DO - 10.1136/ebm.12.6.168 VL - 12 IS - 6 A2 - , Y1 - 2007/12/01 UR - http://ebm.bmj.com/content/12/6/168.abstract N2 - Do vaccines against human papillomavirus (HPV) prevent HPV 16/18 related cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) and adenocarcinoma in situ (AIS) in young women?Ault KA, for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–8.Clinical impact ratings GP/FP/Primary care ★★★★★★⋆ Gynaecology ★★★★★★⋆ Public health ★★★★★★⋆ Design: prespecified combined analysis of 4 randomised controlled trials.Allocation: concealed.*Blinding: blinded (clinicians, participants, outcome assessors, and adjudication committee).*Follow-up period: mean 3 years (maximum 4 y). Follow-up started on day 1 in the intention-to-treat and susceptible populations and 1 month after the third dose of vaccine in the per protocol population.Setting: clinics in North America, Latin America, … ER -